Reply to: “Predictors of sorafenib benefit in patients with hepatocellular carcinoma”

Jordi Bruix; Ann‐Lii Cheng; Josep M. Llovet

doi:10.1016/j.jhep.2017.10.013

Related publications

Article2017

Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial

Roser Pinyol, Robert Montal, T. Takayama, Gar‐Yang Chau, Vincenzo Mazzaferro, S. Roayaie, H.C. Lee, Rtp Poon, N. Kokudo, Z. Zhang, Laia Bassaganyas, Sara Torrecilla, Agrin Moeini, Leonardo Rodríguez‐Carunchio, Edward Gane, Chris Verslype, Adina Croitoru, Umberto Cillo, Manuel de la Mata, L. Lupo, Simone I. Strasser, J.-W. Park, Jordi Camps, María A. Solé, S N Thung, A. Villanueva, Carol E. Peña, G. Meinhart, Jordi Bruix, Josep M. Llovet

Journal of Hepatology

Article2016

Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)

Josep M. Llovet, Philippe Merle, Karl Heinz Weiss, Thomas Yau, Paul J. Ross, Vincenzo Mazzaferro, Jean–Frédéric Blanc, Yuk Ting, Chia Jui Yen, Judit Kocsis, Su Pin Choo, Wattana Sukeepaisarnjaroen, René Gérolami, Jean‐François Dufour, Edward Gane, Baek‐Yeol Ryoo, Markus Peck‐Radosavljevic, Thông Dao, Winnie Yeo, Wisut Lamlertthon, Satawat Thongsawat, Michael Teufel, Heiko Krissel,

Article2017

Circulating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with hepatocellular carcinoma (HCC) in the RESORCE trial

Michael Teufel, Henrik Seidel, Karl Köchert, Gudrun Meinhardt, Richard S. Finn, Josep M. Llovet, Jordi Bruix

Annals of Oncology

Article2017

Protein biomarkers as predictors of outcome with regorafenib (REG) in patients (pts) with hepatocellular carcinoma (HCC) in the RESORCE trial

Michael Teufel, Karl Köchert, Gudrun Meinhardt, Richard S. Finn, Josep M. Llovet, Jordi Bruix

Annals of Oncology

Article2009

814 EVALUATION OF TUMOR PERFUSION AT COMPUTED TOMOGRAPHY AS A TOOL TO DETECT THE EFFECT OF SORAFENIB TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)

María Reig, Jordi Rimola, Alejandro Forner, Carlos Rodríguez de Lope, Josep M. Llovet, Carmen Ayuso, Jordi Bruix

Journal of Hepatology

Reply to: “Predictors of sorafenib benefit in patients with hepatocellular carcinoma”

Abstract

Discussion(0)

Related publications

Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial

Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)

Circulating miRNA biomarkers predicting regorafenib (REG) clinical benefit in patients with hepatocellular carcinoma (HCC) in the RESORCE trial

Protein biomarkers as predictors of outcome with regorafenib (REG) in patients (pts) with hepatocellular carcinoma (HCC) in the RESORCE trial

814 EVALUATION OF TUMOR PERFUSION AT COMPUTED TOMOGRAPHY AS A TOOL TO DETECT THE EFFECT OF SORAFENIB TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)